Docoh
Loading...

PRCT Procept BioRobotics

News

Pro users get this 30m faster
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021
11 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
B of A Securities Initiates Coverage On PROCEPT BioRobotics with Buy Rating, Announces Price Target of $48
11 Oct 21
News, Price Target, Initiation, Analyst Ratings
B of A Securities analyst Bob Hopkins initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy rating and announces Price Target of $48.
Cowen & Co. Initiates Coverage On PROCEPT BioRobotics with Outperform Rating, Announces Price Target of $50
11 Oct 21
News, Price Target, Initiation, Analyst Ratings
Cowen & Co. analyst Joshua Jennings initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform rating and announces Price Target of $50.
Guggenheim Initiates Coverage On PROCEPT BioRobotics with Buy Rating, Announces Price Target of $45
11 Oct 21
News, Price Target, Initiation, Analyst Ratings
Guggenheim analyst Chris Pasquale initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy rating and announces Price Target of $45.
SVB Leerink Initiates Coverage On PROCEPT BioRobotics with Outperform Rating, Announces Price Target of $46
11 Oct 21
News, Price Target, Initiation, Analyst Ratings
SVB Leerink initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform rating and announces Price Target of $46.
Goldman Sachs Initiates Coverage On PROCEPT BioRobotics with Neutral Rating, Announces Price Target of $37
11 Oct 21
News, Price Target, Initiation, Analyst Ratings
Goldman Sachs analyst Amit Hazan initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral rating and announces Price Target of $37.
56 Biggest Movers From Yesterday
17 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
53 Biggest Movers From Yesterday
16 Sep 21
News, Penny Stocks, Short Sellers, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share.
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14)
IPO Previews For The Week
12 Sep 21
News, IPOs
With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
12 Sep 21
News, Penny Stocks, Small Cap, FDA, Top Stories
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week.